Document is current
Any future updates will be listed below
-
Authors
Orbai, Ana-Maria https://orcid.org/0000-0001-8644-8567
Coates, Laura C.
Deodhar, Atul
Helliwell, Philip S.
Ritchlin, Christopher T.
Leibowitz, Evan
Kollmeier, Alexa P.
Hsia, Elizabeth C.
Xu, Xie L.
Sheng, Shihong
Jiang, Yusang
Liu, Yan
Han, Chenglong
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct03162796 at ClinicalTrials.govDocuments that mention this clinical trial
Guselkumab induces robust reduction in acute phase proteins and type 17 effector cytokines in active psoriatic arthritis: results from phase 3 trials
https://doi.org/10.1136/rmdopen-2021-001679
Meaningful Improvement in General Health Outcomes with Guselkumab Treatment for Psoriatic Arthritis: Patient-Reported Outcomes Measurement Information System-29 Results from a Phase 3 Study
https://doi.org/10.1007/s40271-022-00588-6
Sustained and improved guselkumab response in patients with active psoriatic arthritis regardless of baseline demographic and disease characteristics: pooled results through week 52 of two phase III, randomised, placebo-controlled studies
https://doi.org/10.1136/rmdopen-2022-002195
Identification of PsA phenotypes with machine learning analytics using data from two phase III clinical trials of guselkumab in a bio-naïve population of patients with PsA
https://doi.org/10.1136/rmdopen-2022-002934
Guselkumab, an inhibitor of the IL-23p19 subunit, provides sustained improvement in signs and symptoms of active psoriatic arthritis: 1 year results of a phase III randomised study of patients who were biologic-naïve or TNFα inhibitor-experienced
https://doi.org/10.1136/rmdopen-2020-001457
AB0813 GUSELKUMAB-TREATED PATIENTS ACHIEVED CLINICALLY MEANINGFUL IMPROVEMENT IN SYSTEMIC SYMPTOMS AS MEASURED WITH PROMIS INSTRUMENT: RESULTS FROM PHASE-3 PSORIATIC ARTHRITIS TRIAL DISCOVER 1
https://doi.org/10.1136/annrheumdis-2020-eular.2929
POS0969 GENETIC AND MOLECULAR DISTINCTIONS BETWEEN AXIAL PSORIATIC ARTHRITIS AND ANKYLOSING SPONDYLITIS
https://doi.org/10.1136/annrheumdis-2022-eular.1500
Incidence of infections in patients with psoriatic arthritis and axial spondyloarthritis treated with biological or targeted disease-modifying agents: a systematic review and meta-analysis of randomised controlled trials, open-label studies and observational studies
https://doi.org/10.1136/rmdopen-2023-003064
-
Funding
Funding for this research was provided by:
Janssen Research and Development
- License Information
-
More Information
Article History
Accepted: 19 May 2022
First Online: 30 June 2022
Declarations
:
: This study was funded by Janssen Research & Development, LLC.
: Ana-Maria Orbai has received grant/research support from AbbVie, Amgen, Eli Lilly and Company, Celgene, Novartis, Janssen, and Horizon; has received consulting fees from Bristol Myers Squibb, Eli Lilly, Janssen, Novartis, Pfizer, and UCB, and is also a private consultant or advisor for Sun Pharmaceutical Industries, Inc, not in her capacity as a Johns Hopkins faculty member and was not compensated for this service. Laura C. Coates has received grant/research support from AbbVie, Amgen, Celgene, Eli Lilly, Janssen, Novartis, Pfizer, and UCB; speaker fees from AbbVie, Amgen, Biogen, Celgene, Eli Lilly, Galapagos, Gilead, Janssen, Medac, Novartis, Pfizer, and UCB; and consultant fees from AbbVie, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Eli Lilly, Galapagos, Gilead, Janssen, Novartis, Pfizer, and UCB. Laura C Coates is funded by a National Institute for Health Research (NIHR) Clinician Scientist award. The research was supported by the NIHR Oxford Biomedical Research Centre (BRC). The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR, or the Department of Health. We acknowledge the support of the NIHR Clinical Research Network. Atul Deodhar has received consulting fees for participation in Advisory Boards from AbbVie, Amgen, Aurinia, Bristol Myers Squibb, Celgene, Eli Lilly, GlaxoSmithKline, Janssen, MoonLake, Novartis, Pfizer, and UCB; grant/research support from AbbVie, Eli Lilly, GlaxoSmithKline, Novartis, Pfizer, and UCB; and speaker fees from AbbVie, Eli Lilly, Janssen, Novartis, Pfizer, and UCB. Philip S. Helliwell has received consulting fees from Eli Lilly and fees for educational services from AbbVie, Amgen, Novartis, and Janssen. Christopher T. Ritchlin has received grant/research support from UCB Pharma, AbbVie, and Amgen; consulting fees from UCB Pharma, Amgen, AbbVie, Lilly, Pfizer, Novartis, Gilead, and Janssen. Evan Leibowitz is an employee of Janssen Scientific Affairs, LLC, and owns stock in Johnson & Johnson, of which Janssen Scientific Affairs is a wholly owned subsidiary. Alexa P. Kollmeier, Elizabeth C. Hsia, Xie L. Xu, Shihong Sheng, Yan Liu, and Chenglong Han are employees of Janssen Research & Development, LLC, and own stock in Johnson & Johnson, of which Janssen Research & Development is a wholly owned subsidiary. Yusang Jiang is a consultant employed by Cytel, Inc. and funded by Janssen to provide statistical support.
: All procedures performed in this study involving human participants were conducted in accordance with the ethical standards of institutional and/or national research committees and with the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards. The protocol was approved by each site’s governing ethical body.
: Informed consent was obtained from all individual participants included in the study.
: All authors have provided consent for publication of this article.
: The data sharing policy of Janssen Pharmaceutical Companies of Johnson & Johnson is available at. As noted on this site, requests for access to the study data can be submitted through the Yale Open Data Access (YODA) Project site at.
: Not applicable.
: Important intellectual contribution to conception and design, and/or acquisition of data, and/or analysis and interpretation of data provided by AMO, LCC, AD, PSH, CTR, EL, APK, ECH, XLX, SS, YJ, YL, and CH. Critical revisions of the manuscript for important intellectual content provided by AMO, LCC, AD, PSH, CTR, EL, APK, ECH, XLX, SS, YJ, YL, and CH. Final approval of the of the version to be published provided by AMO, LCC, AD, PSH, CTR, EL, APK, ECH, XLX, SS, YJ, YL, and CH. Agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved provided by AMO, LCC, AD, PSH, CTR, EL, APK, ECH, XLX, SS, YJ, YL, and CH.
